| Tuesday, 08 September 2009 | |
|
Today, more biotechs are looking at acquisition as their primary exit strategy. Toban Zolman, director of consulting services at life sciences consulting/software firm ISI, discusses some criteria biotechs will be evaluated on and how these companies can prepare for acquisition. Download Podcast (right click on link to download) Length: 6 min, 43 sec |